Anteris Technologies Global, an Australia-based maker of artificial heart valves, raised $89 million by offering 14.8 million shares at $6, below the as-converted December 5 close of its shares on the ASX ($6.78).
Anteris is a structural heart company focused on patients with aortic stenosis. Its lead product, the DurAVR transcatheter heart valve (THV) system, consists of a single-piece, biomimetic valve made with its proprietary ADAPT tissue-enhancing technology and deployed with its ComASUR balloon-expandable delivery system. To date, a total of 73 patients have been treated with the DurAVR THV system across the US, Canada, and Europe.
Anteris Technologies Global plans to list on the Nasdaq under the symbol AVR. TD Cowen, Barclays, and Cantor Fitzgerald acted as joint bookrunners on the deal.
